Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 83Neoplasm Metastasis 9Prostatic Neoplasms, Castration-Resistant 5Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Castration-resistant Prostate Cancer 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Thrombocytosis 1Prostatic Diseases 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Ovarian Neoplasms 1

Interventions

pembrolizumab 36Carboplatin 28Paclitaxel 23Filgrastim 17Nivolumab 14Gemcitabine 14Cyclophosphamide 14Ifosfamide 13Cisplatin 13Docetaxel 12Specimen Handling 11Etoposide 11olaparib 9Peripheral Blood Stem Cell Transplantation 9Magnetic Resonance Spectroscopy 8fludarabine 6Temozolomide 6Ipilimumab 6Fluorouracil 6Biopsy 6Albumin-Bound Paclitaxel 6rucaparib 5avelumab 5atezolizumab 5Trastuzumab 5Thiotepa 5Taxes 5Standard of Care 5palbociclib 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × abiraterone × Genitourinary × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡